Bruker Corporation (Nasdaq: BRKR), a provider of high performance scientific instruments and high value analytical and diagnostic solutions, announced on Monday that it has launched the Dimension Nexus atomic force microscope (AFM), marking a new standard in cost-effective, large-sample AFM systems.
Revealed on 19 December 2023 at the 2024 MRS Fall Meeting, Dimension Nexus expands the company's renowned Dimension product line, which boasts over 4,600 global installations. Equipped with the advanced NanoScope 6 controller, it offers seamless access to Bruker's proprietary PeakForce Tapping technology and over 50 specialised AFM modes, targeting growing laboratories and multi-user facilities.
Designed with low noise, low drift and open architecture, Dimension Nexus combines high performance with affordability. Its NanoScope 6 controller enhances productivity, while exclusive features like ScanAsyst simplify operations. The system supports advanced modes including AFM-nDMA for viscoelastic analysis and PeakForce QNM for mechanical property mapping. A programmable stage further enables high-throughput, multi-site analysis, making it a versatile solution for cutting-edge research.
Bruker Corporation continues to innovate in post-genomic scientific instrumentation, supporting breakthroughs in life sciences, nanoanalysis and advanced semiconductor research.
Zura Bio announces global Phase 2 TibuSURE trial for systemic sclerosis treatment
Eli Lilly and Co receives approval from FDA for Zepbound
YolTech Therapeutics updates data from Phase I/IIa clinical trial of YOLT-201
AstraZeneca's Tagrisso gains EU approval for advanced lung cancer treatment
Novo Nordisk's CagriSema shows superior weight loss in obesity trial
GSK's Jemperli-Zejula combination shows promise in ovarian cancer
Sapience Therapeutics' ST316 receives US FDA Orphan Drug Designation
Ionis Pharmaceuticals' TRYNGOLZA receives US FDA approval
BioArctic licenses PyroGlu-Aβ antibody programme to Bristol Myers Squibb
Thor Medical signs supply deal with AdvanCell
MOBILion Systems collaborates with Dr Oliver Schmitz to enhance metabolomics analysis
Abilita and Orion partner on antibody therapeutics for oncology and pain
Pharus Diagnostics unveils liquid biopsy test for early pancreatic cancer detection
Mendus reports positive topline data from ovarian cancer trial